【Good News】Shenzhen Cell Valley Invited to Attend CGCS 2024 (5th) International Cell & Gene Therapy China Summit and Honored with the "CGT CDMO Cooperation Morning Star Award"

From May 22 to 24, 2024, Shenzhen Cell Valley was invited to attend the CGCS 2024 (5th) International Cell & Gene Therapy China Summit . As one of the highest-profile annual conferences in the fields of cell and gene therapy, nucleic acid drugs, and organoids, the summit brought together over 200 top global experts in the CGT field as speakers and more than 6,000 industry researchers and practitioners. The conference focused on cutting-edge topics including CGT regulations, clinical development, R&D and manufacturing of cell therapies, CAR-T commercialization, novel cell therapies, and gene therapy, with discussions centered on breakthrough developments in the CGT industry and its commercialization trajectory.

After competing alongside hundreds of CGT companies and undergoing rigorous uation by a panel of authoritative expert judges, Shenzhen Cell Valley was ultimately awarded the "CGT CDMO Cooperation Morning Star Award" .

This honor reflects Shenzhen Cell Valley's sustained deep commitment to the CGT field, particularly in the development and innovation of foundational cell therapy technologies, which has earned high recognition from the industry . As the only domestic provider of one-stop cell and gene therapy solutions with industrial-grade retroviral vector technology (including the PackRV-SS system), Shenzhen Cell Valley's services encompass the full lifecycle management—from early-stage scientific research and development and clinical research, through to commercial production. By continuously empowering the acceleration of biologics R&D, cost reduction, and quality enhancement, the company is dedicated to becoming a trusted partner for clients, helping them serve patients around the world .

Shenzhen Cell Valley firmly believes that deepening technology R&D and refining process innovation are key to building a solid foundation for industrial innovation. Upholding the mission of "Cells benefit all, genes create the future," the company will continue to deepen its efforts in the CGT space, driving transformative industrial development through breakthroughs in critical areas, and providing advanced, comprehensive one-stop CDMO solutions to global partners.